Last updated: September 8, 2026
Dienogest and estradiol valerate is the active-ingredient combination in Bayer’s oral contraceptive Natazia in the United States and Qlaira in several international markets. The product occupies a differentiated position among combined oral contraceptives because it uses estradiol valerate, a precursor to endogenous estradiol, and dienogest, a progestin with antiandrogenic activity. Its commercial trajectory is mature, with brand sales exposed to generic substitution, country-specific reimbursement, and the absence of separately reported product revenue.
What is dienogest and estradiol valerate used for?
Dienogest and estradiol valerate is primarily used for oral contraception. In the United States, Natazia is also indicated for the treatment of heavy or prolonged menstrual bleeding in women who choose oral contraception and have no underlying pathology identified as the cause of the bleeding.[1]
Natazia uses a 28-day regimen containing four different hormone-dose phases:
| Tablet phase |
Estradiol valerate |
Dienogest |
| Days 1-2 |
3 mg |
0 mg |
| Days 3-7 |
2 mg |
2 mg |
| Days 8-24 |
2 mg |
3 mg |
| Days 25-26 |
1 mg |
0 mg |
| Days 27-28 |
Inactive |
Inactive |
The product differs from many established oral contraceptives that combine ethinyl estradiol with levonorgestrel, norethindrone, desogestrel, or drospirenone. Its clinical positioning relies on the estradiol valerate formulation, the four-phase dosing schedule, and the heavy-menstrual-bleeding indication.
How does the combination compare with standard combined oral contraceptives?
| Attribute |
Dienogest/estradiol valerate |
Typical combined oral contraceptive |
| Estrogen component |
Estradiol valerate |
Usually ethinyl estradiol |
| Progestin |
Dienogest |
Varies by product |
| Regimen |
Four-phase, 26 active-tablet schedule |
Usually monophasic or triphasic |
| U.S. indication |
Contraception and selected heavy menstrual bleeding |
Primarily contraception |
| Primary commercial position |
Differentiated branded product |
Broad generic and branded market |
| Generic pressure |
High in mature markets |
Very high |
| Biosimilar exposure |
None |
None |
What is the FDA regulatory status of Natazia?
The FDA approved Natazia on May 6, 2010, for prevention of pregnancy. The agency later approved the heavy menstrual bleeding indication in 2013.[2] Natazia is a small-molecule prescription drug regulated through the abbreviated new drug application, or ANDA, pathway for generic competition.
The product is not a biologic and does not qualify for biosimilar competition. Any future competitors would be conventional generic oral contraceptives required to demonstrate pharmaceutical equivalence and bioequivalence.
What is the Orange Book status of Natazia?
Natazia is listed in the FDA Orange Book as a prescription drug with drug-product patents and exclusivity information administered through the FDA’s approved drug database.[3] The Orange Book is the controlling source for current patent listings, expiration dates, and any active pediatric exclusivity.
Public market analysis should distinguish among:
- FDA-listed patents.
- Patent terms adjusted or extended under U.S. law.
- Regulatory exclusivity.
- Actual commercial availability of an approved generic.
- Litigation settlements that can delay or permit generic launch.
A historical patent listing does not establish that a patent remains enforceable against every proposed generic. Patent validity, claim scope, terminal disclaimers, pediatric extensions, and litigation outcomes must be reviewed separately.
What patents protect dienogest and estradiol valerate?
The patent estate has historically protected the combination’s composition, dosage regimen, and pharmaceutical formulation. Product-specific U.S. patent information should be verified against the latest FDA Orange Book and USPTO records before use in a transaction, launch decision, or litigation assessment.
| Protection category |
Relevance to Natazia/Qlaira |
Commercial effect |
| Active-ingredient combination |
Covers pharmaceutical use of estradiol valerate with dienogest |
Supports product differentiation |
| Regimen patents |
Protects the staged hormone-dose schedule |
Can narrow generic design-around options |
| Formulation patents |
May cover tablet composition, layering, or release characteristics |
Can create manufacturing and bioequivalence hurdles |
| Method-of-use patents |
Relevant to contraception and heavy menstrual bleeding |
May support targeted litigation or labeling restrictions |
| Manufacturing patents |
May cover production of dienogest, estradiol valerate, or tablets |
Usually less visible to ordinary generic substitution |
| Foreign national patents |
Vary by country and filing history |
Produce different launch dates by market |
The original patent protection for the product is mature. The most important remaining barriers are likely to be regulatory implementation, formulation complexity, supply reliability, and commercial economics rather than a long period of unexpired basic composition protection.
What formulations are protected?
Natazia’s formulation is commercially important because the product contains multiple active-tablet strengths in a fixed sequence. A generic applicant must reproduce the required strengths, inactive ingredients where relevant, tablet presentation, packaging configuration, and labeling while meeting bioequivalence requirements.
The four-phase regimen can raise development costs relative to a simple monophasic tablet. It may also create manufacturing and quality-control requirements across several tablet types. Those factors can reduce the number of immediate generic entrants even after core patent barriers weaken.
When does dienogest and estradiol valerate lose exclusivity?
The product’s principal U.S. regulatory and patent exclusivity has already matured or is approaching full maturity, depending on the specific patent and jurisdiction. Natazia was approved in 2010, and the standard five-year new chemical entity exclusivity period ended in 2015.[2]
The practical exclusivity timeline is:
| Milestone |
Timing |
| U.S. approval of Natazia |
May 2010 |
| Standard new chemical entity exclusivity |
Ended in 2015 |
| Heavy menstrual bleeding indication |
Approved in 2013 |
| Core product patent period |
Primarily a 2020s issue, subject to patent-specific adjustments |
| Generic-entry risk |
High in the United States and mature international markets |
| Current commercial phase |
Late lifecycle |
The exact generic-entry date depends on the latest Orange Book listing, patent litigation, any Paragraph IV certification, court orders, and settlement terms. No single “loss of exclusivity” date applies globally because Natazia and Qlaira have different national approvals, patents, reimbursement rules, and launch histories.
Which companies are challenging Natazia or Qlaira?
The relevant competitive field includes generic manufacturers with experience in complex oral contraceptive products. Potential participants include Teva, Mylan/Viatris, Sandoz, Lupin, Amneal, and other regional manufacturers. A company’s presence in the oral contraceptive market does not establish that it has filed an ANDA or challenged a specific Natazia patent.
A definitive Paragraph IV analysis requires review of:
- FDA Paragraph IV litigation records.
- Hatch-Waxman complaints filed in federal district courts.
- ANDA applicant identity.
- Orange Book patent certifications.
- Court docket developments.
- Any settlement or license agreement.
No material conclusion about an active Paragraph IV challenge should be drawn from generic availability in non-U.S. markets. Qlaira has been marketed in several countries under regulatory systems that do not use the U.S. ANDA and Paragraph IV framework.
What patent litigation affects dienogest and estradiol valerate?
The commercial litigation risk is concentrated in the United States. The relevant claims would typically involve:
- The combination of estradiol valerate and dienogest.
- The multi-phase dosing sequence.
- Specific tablet formulations.
- Methods of contraception.
- Treatment of heavy menstrual bleeding.
- Packaging and regimen presentation.
The absence of a widely reported, current high-value U.S. litigation campaign would indicate that the product is in a late-stage lifecycle rather than that the patent estate is commercially irrelevant. For a mature contraceptive, the economic value of litigation may be limited by the product’s relatively modest standalone revenue and the availability of alternative contraceptives.
How strong is the patent estate for Natazia?
The estate is technically differentiated but commercially moderate in strength.
Strengths
- The product has a distinct active-ingredient pairing.
- The four-phase regimen creates formulation and packaging complexity.
- The heavy menstrual bleeding indication provides an additional use case.
- Generic applicants must meet bioequivalence requirements for a multi-strength product.
- Foreign patent and regulatory positions can vary materially by market.
Weaknesses
- The approval date places the product in a mature lifecycle.
- Standard U.S. exclusivity has expired.
- Contraceptive products face substantial therapeutic substitution.
- Alternative generic oral contraceptives are widely available.
- A generic applicant may challenge individual patents rather than copy every protected commercial attribute.
- Product revenue is not separately disclosed, limiting the economic value of prolonged litigation.
The patent estate is therefore more useful for managing the timing and conditions of generic entry than for sustaining long-term monopoly pricing.
What is the commercial market for dienogest and estradiol valerate?
The product competes in the global combined oral contraceptive market, which is large but highly fragmented. Key demand drivers include:
- Number of women seeking reversible contraception.
- Access to prescription gynecology services.
- Insurance coverage and pharmacy benefit design.
- Preference for estradiol-based products.
- Diagnosis and treatment of heavy menstrual bleeding.
- Adherence to a 28-day regimen.
- Physician familiarity with newer progestins.
- Generic substitution policies.
Natazia’s market position is constrained by the scale of low-cost alternatives. In contraception, many patients and payers view products as substitutable unless a specific clinical, tolerability, or bleeding-control rationale supports the branded product.
What is the revenue exposure for Bayer?
Bayer does not generally report Natazia or Qlaira as standalone global revenue lines. The products are included within Bayer’s Pharmaceuticals reporting, particularly the Women’s Health portfolio or related prescription-product disclosures.[4]
This prevents a precise public estimate of:
- Annual Natazia revenue.
- Annual Qlaira revenue.
- U.S. versus international sales.
- Gross-to-net deductions.
- Brand share after generic entry.
- Product-level operating margin.
The financial trajectory is best characterized as mature and declining or volatile rather than growth-oriented. Revenue depends on continued branded prescribing, reimbursement, geographic availability, and the timing of generic entry. Bayer’s broader Women’s Health business includes higher-revenue products and does not provide a clean proxy for Natazia performance.
What is the financial trajectory of dienogest and estradiol valerate?
The expected lifecycle pattern is:
| Phase |
Financial characteristics |
| Launch period, 2010-2013 |
Prescriber education, indication expansion, distribution buildout |
| Growth and positioning, approximately 2013-2018 |
Adoption supported by contraception and heavy menstrual bleeding use |
| Maturity, approximately 2019 onward |
Price pressure, therapeutic substitution, limited volume growth |
| Generic-risk phase |
Potential rapid erosion in U.S. brand volume and net price |
| Long tail |
Residual brand demand, international sales, and niche prescribing |
The heavy menstrual bleeding indication improves the product’s commercial profile compared with a contraception-only product. It does not remove generic risk because competitors may target contraception first, while physicians can use alternative products or nonhormonal therapies for bleeding disorders.
Revenue erosion after generic entry can be faster in the United States than in some international markets because U.S. pharmacy benefit managers and insurers apply automatic substitution and formulary controls. In markets with branded-generic competition, the originator may retain volume but at lower prices.
What generic launch scenarios exist?
Scenario 1: No near-term U.S. generic launch
A complex regimen, limited projected revenue, or unresolved patent claims could delay entry. Bayer would retain branded pricing but would still face formulary pressure.
Scenario 2: One approved generic entrant
A first generic could obtain favorable substitution status and capture a substantial share of U.S. prescriptions. Bayer could respond through contracting, patient support, pricing, or channel management.
Scenario 3: Multiple generic entrants
Several approved products would produce sharper price erosion. The brand could retain a smaller cash-pay or physician-preference segment, but reimbursement pressure would intensify.
Scenario 4: Indication-limited competition
A generic may enter with a label focused on contraception while patent or labeling disputes affect the heavy menstrual bleeding indication. The practical effect would depend on state substitution rules, prescriber behavior, and the generic label.
Scenario 5: International erosion before U.S. entry
Generic or local-brand competition may expand outside the United States first. That outcome would reduce Qlaira revenue while leaving U.S. patent and regulatory issues unresolved.
How does Natazia compare with competing contraceptives?
| Product category |
Main differentiator |
Generic pressure |
Commercial risk |
| Dienogest/estradiol valerate |
Estradiol-based, four-phase regimen |
High |
Mature branded product |
| Ethinyl estradiol/levonorgestrel |
Low cost and extensive use |
Very high |
Commodity pricing |
| Ethinyl estradiol/drospirenone |
Bleeding control and antiandrogenic positioning |
High |
Multiple generic options |
| Norethindrone acetate/ethinyl estradiol |
Established physician familiarity |
Very high |
Broad substitution |
| Progestin-only oral contraceptives |
Estrogen-free option |
Increasing |
Different safety and adherence profile |
| Long-acting reversible contraception |
Device-based duration and adherence |
Product-specific |
Competes for the same patient population |
Natazia’s strongest commercial argument is differentiation, not cost. Its weakest point is the availability of inexpensive oral, implant, injectable, intrauterine, and transdermal alternatives.
Are there licensing deals involving dienogest and estradiol valerate?
The product is associated with Bayer’s women’s health franchise and the historical Schering/Jenapharm development lineage. No major recent licensing transaction has publicly established a separate, high-value commercial platform around the Natazia/Qlaira combination.
Any regional commercialization, supply, or distribution agreement should be evaluated separately from ownership of the underlying patents. Brand ownership, marketing rights, manufacturing rights, and local regulatory sponsorship can be held by different entities.
What manufacturing and intellectual-property barriers remain?
The main barriers are operational and regulatory:
- Reliable supply of dienogest and estradiol valerate.
- Production of multiple tablet strengths.
- Consistent tablet sequencing and packaging.
- Bioequivalence across a complex regimen.
- Stability and content-uniformity testing.
- Country-specific labeling and pharmacovigilance obligations.
- Patent clearance for formulation and method-of-use claims.
- Commercial scale sufficient to offset development and launch costs.
These barriers may limit the number of entrants but are unlikely to preserve a durable premium once technically capable generic manufacturers enter.
Key Takeaways
- Dienogest and estradiol valerate is marketed as Natazia in the United States and Qlaira in multiple international markets.
- The product combines estradiol valerate with dienogest in a four-phase oral contraceptive regimen.
- Natazia received FDA approval in 2010 and later gained an indication for selected heavy menstrual bleeding.
- Standard regulatory exclusivity has expired, placing the product in a mature lifecycle.
- Patent protection is product-specific and must be confirmed through current FDA Orange Book and USPTO records.
- The product is not a biologic and has no biosimilar exposure.
- Its formulation and multi-strength regimen can create generic development hurdles, but those barriers are unlikely to support long-term premium pricing.
- Bayer does not separately disclose Natazia or Qlaira revenue, preventing a precise product-level financial forecast.
- The likely financial trajectory is stable-to-declining brand revenue followed by sharper erosion if U.S. generic substitution becomes available.
- Competitive pressure comes from low-cost combined oral contraceptives, progestin-only products, and long-acting reversible contraceptives.
FAQs
Is dienogest and estradiol valerate the same as Natazia?
Yes. Natazia is Bayer’s U.S. brand containing dienogest and estradiol valerate. Qlaira is the principal international brand name in several markets.
Does dienogest and estradiol valerate have biosimilar risk?
No. The product is a small-molecule oral drug. Competition would arise through generic drugs approved under national generic-drug pathways, not biosimilar applications.
Is Natazia still protected by patents?
Potentially, depending on the specific patent, claim, jurisdiction, and current Orange Book status. The product’s original approval and standard exclusivity periods are mature, but individual formulation or regimen patents must be reviewed separately.
Can a generic copy Natazia’s four-phase regimen?
A generic applicant can seek approval for an equivalent product, but it must satisfy applicable pharmaceutical-equivalence, bioequivalence, labeling, manufacturing, and patent requirements. The multi-phase design can increase development complexity.
What is the investment significance of Natazia revenue?
Natazia is unlikely to be a separately material driver of Bayer’s consolidated financial results because Bayer reports broader pharmaceutical and women’s health categories. Its value is primarily a mature portfolio cash flow, with downside linked to generic timing and reimbursement pressure.
References
- U.S. Food and Drug Administration. (2022). Natazia (estradiol valerate and estradiol valerate/dienogest) prescribing information.
- U.S. Food and Drug Administration. (2010). FDA approves Natazia for prevention of pregnancy.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Bayer AG. (2023). Annual report 2023.
